Site is Being Upgraded

Cardiac hypertrophy and fibrosis

September 3, 2018

Regular dark chocolate consumption may insulate your heart against cardiac dysfunction: Chocolate-derived compound theobromine-based adjunct therapy for cardiac hypertrophy and fibrosis: Theobromine,  one of the main components of dark chocolate, decreases Mir-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 4/September/2018, 1.42 am

Introduction: What they say:   A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular […]
August 27, 2018

A sere(ne)laxin-way to stay free of cardiac diseases: Serelaxin-based therapy for attenuating pathogenesis-associated with Myocardial infarction: Serelaxin, a recombinant Relaxin-2,  decreases IRF3 (Interferon regulatory transcription factor-3), GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up-regulation of its target gene, 27/August/2018, 11.25 pm

Introduction: What they say: A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and […]
August 26, 2018

Serelaxin (SLX)-based therapy for cardiomyocyte proliferation and heart regeneration: Serelaxin (SLX), a recombinant relaxin-2, decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 26/August/2018, 7.10 pm

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory […]
August 24, 2018

Serelaxin (SLX)-based therapy for cardiac hypertrophy and fibrosis: Serelaxin (SLX), a recombinant relaxin-2, decreases MiR-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 24/August/2018, 2.52 pm

Introduction: What they say: A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular […]